Kerry Benenato

Kerry Benenato serves as the Chief Platform Officer at Sail Biomedicines since February 2024, following the role of Chief Scientific Officer at 76Bio, Inc. from October 2022 to January 2024. Prior experience includes a substantial tenure at Moderna from September 2014 to October 2022, where positions included Vice President of Platform Chemistry and Formulation Discovery, Vice President of Platform Chemistry, and various senior director roles. Kerry's career began at AstraZeneca, where responsibilities spanned from Principal Scientist to Team Leader between June 2012 and September 2014, along with earlier roles at AstraZeneca R&D and AstraZeneca Pharmaceuticals. Academic qualifications include a Ph.D. in Organic Chemistry from Boston College and a B.S. in Chemistry and Mathematics from Providence College.